IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia
Authors:
Open Access
- 6 June 2024
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 109 (12) , 3904-3917
Abstract
IKZF1 deletions occur in 10-15% of patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict a poor outcome. However, the impact of IKZF1 loss on sensitivity to drugs used in contemporary treatment protocols has remained underexplored. Here we show in experimental models and in patients that loss of IKZF1 promotes resistance to cytarabine (AraC), a key component of both upfront and relapsed treatment protocols. We attribute this resistance, in part, to diminished import and incorporation of AraC due to reduced expression of the solute carrier hENT1. Moreover, we found elevated mRNA expression of Evi1, a known driver of therapy resistance in myeloid malignancies. Finally, a kinase directed CRISPR/Cas9-screen identified that inhibition of either mediator kinases CDK8/19 or casein kinase 2 can restore response to AraC. We conclude that this high-risk group of patients could benefit from alternative antimetabolites, or targeted therapies that re-sensitize leukemic cells to AraC.Keywords
This publication has 49 references indexed in Scilit:
- The oncogene and developmental regulator EVI1: Expression, biochemical properties, and biological functionsGene, 2007
- Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR dataLeukemia, 2007
- Problems Related to Resistance to Cytarabine in Acute Myeloid LeukemiaLeukemia & Lymphoma, 2004
- Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemiaBlood, 2002
- In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemiaBritish Journal of Haematology, 2002
- Nucleoside analogues: mechanisms of drug resistance and reversal strategiesLeukemia, 2001
- Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage.International Journal of Molecular Medicine, 2000
- Clinical pharmacokinetics of anti-metabolites.1993
- RELATIONSHIPS AMONG ARA-CTP POOLS, FORMATION OF (ARA-C)DNA, AND CYTO-TOXICITY OF HUMAN-LEUKEMIC CELLS1984
- Cytosine Arabinoside Influx and Nucleoside Transport Sites in Acute LeukemiaJournal of Clinical Investigation, 1982